Therapeutic Response

v::ALK status confers therapeutic sensitivity to Alectinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Alecensaro (alectinib) [product monograph]. HC. Health Canada approved alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.
Alecensa (alectinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.
Alecensa (alectinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to alectinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.